North Atlantic Industries (NAI) is emerging as a compelling force in rugged embedded electronics, thanks to its unique Configurable Open Systems Architecture (COSA®) and AS9100-certified manufacturing. As global defence spending...
Key Takeaways The £6.2 billion ($8 billion) merger between Paramount Global and Skydance Media has received final regulatory approval from the US Federal Communications Commission (FCC). The deal is set...
Key Takeaways Google Cloud achieved an annual revenue run rate exceeding $53 billion in Q2 2025, marking a significant 28% year-on-year growth and demonstrating accelerating market penetration. Alphabet has increased...
Key Takeaways Major technology firms are projected to spend a collective $200 billion on capital expenditure in 2025, a significant increase from previous years, driven primarily by investments in AI...
Amidst a backdrop of fluctuating economic signals in 2025, a notable group of stocks across diverse sectors has reached 52-week highs, reflecting robust investor confidence in specific industries. This surge,...
The prospect of Tesla expanding its robotaxi service into Nevada signals a critical juncture for the company as it seeks to diversify beyond traditional vehicle sales amid a softening outlook...
Key Takeaways Market Realignment: AMD’s server CPU revenue share surpassed 33% in Q1 2025, with x86 unit share reaching approximately 23%, indicating a significant shift in a market long dominated...
Key Takeaways China maintains its lead in global manufacturing, accounting for approximately 31% of worldwide output, a central factor in ongoing US trade negotiations. The US trade deficit with China...
The spectre of a full-blown trade war between the European Union and the United States has re-emerged with renewed intensity, as both sides prepare for a possible exchange of punitive...
GH Research PLC is making waves in the psychedelic therapeutics sector, presenting a promising opportunity with its novel inhaled mebufotenin formulation, GH001, targeting treatment-resistant depression. With impressive Phase 2 trial...
